Customs Valuation Karachi has re-set import values for 11 China-made medical items, excluding major brands, after a review under the Customs Act 1969.
Fresh Customs Valuations Issued After Review
The customs value of 11 classes of imported Chinese medical equipment has been revised in Karachi by the Directorate General of customs Valuation with new standards set on the duties and taxes. The relocation is based on a review order that in part overturned a previous statutory valuation decision and ordered officers to re-fair declared prices in accordance with the customs act 1969.
The new customs rates are now to apply to various frequently imported products such as alcohol swabs, heparin caps, nebulizers and oxygen masks, nasal oxygen cannulas, spinal needles, ECG electrodes, disposable surgical staplers, aneroid devices, three-way stopcocks and three-ball spirometer. These products are common in hospitals, clinics and diagnostic centers, which implies that the new valuation may have an impact on the pricing, the import prices and the tendering prices in the healthcare industry.
Major International Brands Excluded from Revised Values
The re-determined values, which were explained by customs, do not extend to a number of major international brands, even in case their products are produced in China. Brands that will not be covered by the new ruling are Omron, Rossmax, Certeza, Beurer, Citizen, Accu Chek, Accusure and B Braun.
This implies that these branded devices will still be evaluated individually, with regard to their own transactional values, and supporting documentation, and not the generic standards established in the most recent ruling. In the case of distributors and hospitals that depend on established international brands, the difference matters since it maintains brand-specific pricing frameworks and cushions against under- or over-pricing based on generic imports which are cheap.
Earlier Valuation Ruling Challenged Under Review Provisions
The reviewed customs values are the result of a case against the previous value determination judgment made pursuant to Section 25A of the Customs Act 1969. Stakeholders have used Section 25D that provides aggrieved parties the right to request a review of valuation decisions. The Director General of Customs Valuation responded by suspending the decision that the given items were selected and he directed the valuation directorate to perform a new exercise after duly following the valuation hierarchy stipulated in Section 25 of the Act.
In this direction, Customs sent notices to importers and other stakeholders, where they sought comments and supporting documents. Meetings were conducted to recommence the review of values and the importers also sought to have two items revisited, saying that over 90 days had passed since the initial ruling. The idea behind the process was to make the process more transparent and evidence-based, and to have the broader industry input.
Traditional Valuation Methods Found Hard to Apply
According to the officials, some of the usual ways of valuation were not easy to implement in this instance. The approaches to the same and similar goods could not be effective due to a small and unequal import data on the comparable goods. The cross-check method of market surveys to a large extent also was not yielding any consistent results since there is a wide range of price variations across outlets and regions.
The method of computing value was also carried out which would normally be based on the manufacturing cost data in the country of export. This method was however to be discarded as adequate cost breakdowns on the side of suppliers could not be secured. The authorities could not build the correct computed values of the items under consideration without having credible information on the costs of production, freight, overheads, and margins.
Final Values Set Using Residual Method Under Section 25
In view of these constraints, Customs finally concluded the recalculated import values as per Section 25(9), the Customs Act coupled with the applicable Customs Rules as per the Section 25(6). This so-called residual approach enables the authorities to make reasonable judgment and flexibility whilst remaining within the legal valuation framework especially when other approaches prove to be impractical or give unreliable valuations.
This approach has been declared by the directorate to be a balanced measure to limit under-invoicing and at the same time prevent arbitrary and excessive valuations. To importers, the new values are more transparent on the duty and taxation consequences of importing most of the frequently used Chinese medical products. To the government, the review will be aimed at enhancing protection of revenue and providing a more even playing ground between compliant importers and those who may have previously made use of under-valued declarations.
The revised valuation schedules are now expected to be reviewed by the hospitals, distributors and procurement agencies and consider the updated customs values as part of their pricing and tender strategy. The subsequent tussles will probably have to undergo the same discursive procedures followed in the case, which supports the importance of Section 25-predicated procedures in the formation of the value of imported medical equipment in the border.
